Speaker Profile
M.D., Ph.D., CEO, Endometrics Ltd.
Biography
Dr. Yana Aznavour is building a new generation of non-invasive diagnostics for women’s health, starting with a menstrual-blood-based test for endometriosis and expanding toward broader gynecologic and precision-oncology applications. Her work sits at the intersection of clinical medicine, molecular biology, and translational bioinformatics, with a focus on converting complex biological signals into clinically actionable tools. She has led multidisciplinary teams across academia, healthcare systems, and early-stage biotech to advance biomarker discovery, clinical validation, and regulatory strategy. Her research and innovation have been recognized by major professional societies in minimally invasive gynecology. She is the youngest recipient of the Jordan Phillips Award for the best research in minimally invasive gynecology by the American Association of Gynecologic Laparoscopists. Passionate about closing longstanding diagnostic gaps in women’s health, she advocates for rigorous science, clinically integrated development, and evidence-driven commercialization pathways that prioritize real-world utility and patient impact.
Talk
Unlocking Menstrual Blood for Molecular Diagnostics
Menstrual blood is emerging as a rich, non-invasive diagnostic specimen. Endometrics is building a clinically integrated platform, starting with a validated at-home test for endometriosis and expanding into gynecologic oncology. We combine proprietary biobanking and advanced bioinformatics for biomarker discovery, with home collection kits and CLIA-grade infrastructure to deliver clinically actionable diagnostics at scale.
Clinical Dx Showcase:
Endometrics Ltd.
Endometrics is a women’s health diagnostics company advancing molecular technologies for non-invasive gynecologic care. Backed by UC Berkeley SkyDeck, the company won first place at the WHIS Startup Showcase and is a finalist in the NIH RADx ENDO Challenge. Endometrics participates in the Blue Cross Blue Shield Accelerator, working with clinical and industry partners to scale next-generation women’s health diagnostics.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
